Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen

Autor: Leen Rigouts, Pauline Lempens, Bouke C. de Jong, Conor J. Meehan, Tom Decroo, K. J. M. Aung, Armand Van Deun, Mohammad Ali Hossain

Publikováno v: International Journal of Infectious Diseases, Vol 100, Iss, Pp 357-365 (2020)
International journal of infectious diseases
International Journal of Infectious Diseases

Highlights • Shorter treatment regimen for multidrug-resistant tuberculosis. • Effect of companion drug resistance on adverse outcomes. • Gatifloxacin and isoniazid minimum inhibitory concentration. • Whole-genome sequencing. • Non-eligibil

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b0607183cb33511a30b72e94a76ade0
http://www.sciencedirect.com/science/article/pii/S120197122030672X

Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB

Autor: Christopher Kuaban, Hans L. Rieder, A. Van Deun, K. J. M. Aung, J Noeske, Alberto Piubello, Tom Decroo

Publikováno v: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 23(9)

SETTING: Data were collected from patients starting one of the shorter treatment regimens (STRs) for multidrug-resistant tuberculosis (MDR-TB) in Bangladesh, Niger or Cameroon.OBJECTIVE: To estimate the effect of either a gatifloxacin (GFX), moxiflox

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::103290bc3a59cf0df4f4d7f5a3479c5d
https://pubmed.ncbi.nlm.nih.gov/31615602

Specific gyrA gene mutations predict poor treatment outcome in MDR-TB

Autor: K. J. M. Aung, Nele Coeck, Conor J. Meehan, Leen Rigouts, M A Hossain, B. C. de Jong, W B de Rijk, Hans L. Rieder, A. Van Deun, K Fissette, M Gumusboga

Publikováno v: Journal of Antimicrobial Chemotherapy
The journal of antimicrobial chemotherapy

Objectives Mutations in the gyrase genes cause fluoroquinolone resistance in Mycobacterium tuberculosis. However, the predictive value of these markers for clinical outcomes in patients with MDR-TB is unknown to date. The objective of this study was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d10c3815b0dab15775351f03a7bbc1f5
http://europepmc.org/articles/PMC4710215

Anti-tuberculosis drug resistance in Bangladesh: reflections from the first nationwide survey

Autor: S M M, Kamal, A, Hossain, S, Sultana, V, Begum, N, Haque, J, Ahmed, T M A, Rahman, K A, Hyder, S, Hossain, M, Rahman, Chowdhury R, Ahsan, R A, Chowdhury, K J M, Aung, A, Islam, R, Hasan, A, Van Deun

Publikováno v: The International Journal of Tuberculosis and Lung Disease. 19:151-156

Objective To determine the prevalence of tuberculosis (TB) drug resistance in Bangladesh. Design Weighted cluster sampling among smear-positive cases, and standard culture and drug susceptibility testing on solid medium were used. Results Of 1480 pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4644f2526f92a0017ae26da873b0bf2b
https://doi.org/10.5588/ijtld.14.0200

Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients

Autor: Hans L. Rieder, K. J. M. Aung, Mahfuzur R. Sarker, P. K. Das, M A Hossain, E. Declercq, A. Van Deun

SUMMARY SETTING: Tuberculosis (TB) program, Damien Foundation Projects, Bangladesh. OBJECTIVE: To summarize the outcome and its determinants of the first treatment for multidrug-resistant TB using a standardized regimen consisting of a minimum 9 mont

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ca80035d42c353317d94298727d6849
https://www.zora.uzh.ch/id/eprint/105660/